SILO Stock Catalyst: Silo Pharma Granted US Patent for PTSD Treatment

Jan 7, 2025 · 7:45pm ET

Company prepares for SPC-15 clinical trial.

Max move

+200.9%

High of day $50.55

Sparker timei

7:45pm ET

SILO · Jan 7, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Silo Pharma, Inc. (XNAS: SILO) announced on January 8, 2025, that it has been awarded a US patent for its innovative treatment targeting post-traumatic stress disorder (PTSD). The company is now gearing up for the SPC-15 clinical trial to further evaluate the treatment's efficacy.

The awarded patent underscores Silo Pharma's commitment to advancing therapeutic solutions for mental health conditions. With 12,159,554.6268 shares in free float and 13,318,300 shares outstanding, the company continues to focus on its research and development efforts in the biotechnology sector.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time SILO sparks.

Download Sniper App →

Catch the next SILO-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →